<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9428">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698043</url>
  </required_header>
  <id_info>
    <org_study_id>A83_10BE2223</org_study_id>
    <nct_id>NCT05698043</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg</brief_title>
  <official_title>An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and the Tolerability of CKD-386(5) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to&#xD;
      evaluate the pharmacokinetics and the tolerability of CKD-386(5) with co-administration of&#xD;
      D013, D326, and D337 in healthy adult volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 5, 2023</start_date>
  <completion_date type="Anticipated">June 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-386(5)</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-386(5)</measure>
    <time_frame>Pre-dose (0 hour), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours</time_frame>
    <description>Maximum plasma concentration of the drug</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension and Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition&#xD;
Period 2: CKD-386(5)- A single oral dose of 1 tablet under fasting condition&#xD;
Period 3: D013, D326, D337- A single oral dose of 3tablets under fasting condition&#xD;
Period 4: CKD-386(5)- A single oral dose of 1 tablet under fasting condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-386(5)- A single oral dose of 1 tablet under fasting condition&#xD;
Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition&#xD;
Period 3: CKD-386(5)- A single oral dose of 1 tablet under fasting condition&#xD;
Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-386(5)</intervention_name>
    <description>Test</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013, D326, D337</intervention_name>
    <description>Reference</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers aged ≥ 19 years&#xD;
&#xD;
          2. Weight ≥55kg with calculated body mass index (BMI) of 18 to 30 kg/m2&#xD;
&#xD;
          3. Those who meet the blood pressure criteria during screening tests:&#xD;
&#xD;
               -  Systolic Blood Pressure: 90 to 139 mmHg&#xD;
&#xD;
               -  Diastolic Blood Pressure: 60 to 89 mmHg&#xD;
&#xD;
          4. Those who have no congenital diseases or chronic diseases and have no abnormal&#xD;
             symptoms or findings.&#xD;
&#xD;
          5. Those who are eligible for clinical trials based on laboratory(hematology, blood&#xD;
             chemistry, serology, urology) and 12-lead ECG results at screening.&#xD;
&#xD;
          6. Those who agree to contraception during the participation of clinical trial.&#xD;
&#xD;
          7. Individuals who voluntarily decide to participate and agree to comply with the&#xD;
             cautions after fully understand the detailed description of this clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who received investigational products or participated in bioequivalence tests&#xD;
             within 6 months before the first administration of clinical trial drugs.&#xD;
&#xD;
          2. Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as&#xD;
             barbiturates, within 1 month before the first dosing date, or who have used drugs that&#xD;
             may interfere with this study within 10 days before the first dosing day (However,&#xD;
             clinical investigational drugs) Participation is possible in consideration of&#xD;
             pharmacokinetic and pharmacodynamic characteristics such as interaction with&#xD;
             concomitant drugs and half-life of concomitant drugs)&#xD;
&#xD;
          3. Those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or&#xD;
             received blood transfusion within a 4 weeks.&#xD;
&#xD;
          4. Those who have a history of gastrointestinal surgery except simple appendectomy and&#xD;
             hernia surgery.&#xD;
&#xD;
          5. Those who exceed an alcohol and cigarette consumption than below criteria&#xD;
&#xD;
               -  Alcohol: Man_21 glasses/week, Woman_14 glasses/week (1 glass: Soju 50mL, Wine&#xD;
                  30mL, or beer 250mL)&#xD;
&#xD;
               -  Heavy Smoking: 20 cigarettes/day&#xD;
&#xD;
          6. Patients with the following diseases&#xD;
&#xD;
               -  Patients with hypersensitivity to the main constituents or components of the&#xD;
                  investigational drug&#xD;
&#xD;
               -  Severe hepatic impairment, biliary atresia or cholestasis&#xD;
&#xD;
               -  Patients with hereditary angioedema or with a history of angioedema in the&#xD;
                  treatment of ACE inhibitors or angiotensin II receptor antagonists&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Patients with moderate to severe renal impairment [glomerular filtration rate&#xD;
                  (eGFR) &lt;60 mL / min / 1.73m^2]&#xD;
&#xD;
               -  Renal vascular hypertension patients&#xD;
&#xD;
               -  Patients with active liver disease, including unexplained persistent serum&#xD;
                  transaminase elevations or elevated serum transaminase elevations greater than&#xD;
                  three times the normal upper limit&#xD;
&#xD;
               -  Patients with myopathy or have a history of family or genetic history of myopathy&#xD;
&#xD;
               -  Hypothyroidism&#xD;
&#xD;
               -  If you have a history of muscle toxicity for other HMG-CoA converting enzymes or&#xD;
                  fibrate class drugs&#xD;
&#xD;
          7. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency&#xD;
             or glucose-galactose malabsorption.&#xD;
&#xD;
          8. Those who are deemed insufficient to participate in this clinical study by&#xD;
             investigators.&#xD;
&#xD;
          9. Woman who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaewoo Jaewoo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H Plus Yangji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaewoo Kim, M.D.</last_name>
    <phone>+82-70-4665-9193</phone>
    <email>m3116@newyjh.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H plus Yangji hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Jaewoo Kim, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 16, 2023</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

